ClinicalTrials.gg
CompletedNCT06167720Updated Dec 15, 2023

Suicide Risk Prediction in Cancer Patients

An observational study in Cancer, sponsored by Fang Tang. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Fang Tang · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
176,000
Sex
All
01

Study summary

Previous studies have found that the suicide risk of cancer patients is influenced by socioeconomic factors, clinical characteristics, and environmental factors. But prediction model with multiple predictors for suicide risk in cancer patients is limited.

The aim of this study is to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, based on retrospective cohorts, and to establish a suicide risk prediction model with multiple predictors for cancer patients.

Read the detailed description

Cancer is a serious public health concern, with almost 10 million people dying from cancer in 2020. Previous studies have reported that cancer patients are more likely to die by suicide than the general public, especially in the six months to one year following cancer diagnosis. Since suicide is a result of the interaction of various factors such as socioeconomic factors, clinical characteristics, and environmental factors, it is necessary to construct a multivariate prediction model to predict the suicide risk in cancer patients.

A retrospective cohort of cancer patients based on the Surveillance, Epidemiology, and End Results (SEER) program database was used to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, and to establish prediction model with multiple predictors for cancer patients. Another retrospective cohort conducted from Shandong Multi-Center Healthcare Big Data Platform (SMCHBDP) was used to verify the predictive ability and generalization ability of the prediction model.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Cancer patients
  • Suicide risk
  • Prediction model
  • Meteorological factors
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 176,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Fang Tang is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients in the Surveillance, Epidemiology, and End Results (SEER) program database and Shandong Multi-Center Healthcare Big Data Platform (SMCHBDP).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cancer patients in SEER database and SMCHBDP

Exclusion criteria

Exclusion Criteria:

  1. No certain cause of death
  2. Missing area code
  3. Lost to follow-up
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
176,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Cancer patients cohort in SEER database

    A retrospective cohort of cancer patients based on the Surveillance, Epidemiology, and End Results (SEER) program database was used to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, and to establish prediction model with multiple predictors for cancer patient

  • Cancer patients cohort in SMCHBDP

    Retrospective cohort conducted from Shandong Multi-Center Healthcare Big Data Platform (SMCHBDP) was used to verify the predictive ability and generalization ability of the prediction model.

06

What researchers measure

Primary outcomes

  1. Mortality attributed to suicide or self-inflicted injury

    The main outcome was mortality attributed to suicide or self-inflicted injury after cancer diagnosis.

    Time frame: 1979-2021

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
    Jinan, Shandong 250014, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 1979 to primary completion in Dec 2021, 515 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 12, 2023
StartActual
Jan 1, 1979
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2021
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06167720
Lead sponsor
Fang Tang
Responsible party
Fang Tang (Doctor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Dec 12, 2023
Start date
Jan 1, 1979
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Dec 15, 2023

Study contacts

Fang Tang, Doctor
principal investigator · The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion